Review



intracellular fe 2 contents  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    Elabscience Biotechnology intracellular fe 2 contents
    TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.
    Intracellular Fe 2 Contents, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 482 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/intracellular+fe+2+contents/pmc12515868-80-20-34?v=Elabscience+Biotechnology
    Average 97 stars, based on 482 article reviews
    intracellular fe 2 contents - by Bioz Stars, 2026-08
    97/100 stars

    Images

    1) Product Images from "Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation"

    Article Title: Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation

    Journal: Frontiers in Pharmacology

    doi: 10.3389/fphar.2025.1654108

    TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.
    Figure Legend Snippet: TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.

    Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Comparison, Two Tailed Test



    Similar Products

    intracellular fe 2 contents  (Elabscience Biotechnology)
    97
    Elabscience Biotechnology intracellular fe 2 contents
    TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.
    Intracellular Fe 2 Contents, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/intracellular+fe+2+contents/pmc12515868-80-20-34?v=Elabscience+Biotechnology
    Average 97 stars, based on 1 article reviews
    intracellular fe 2 contents - by Bioz Stars, 2026-08
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.

    Journal: Frontiers in Pharmacology

    Article Title: Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation

    doi: 10.3389/fphar.2025.1654108

    Figure Lengend Snippet: TBMS1 caused HSF ferroptosis. (A) The volcano plot displays significantly differentially-expressed genes (DEGs) in TBMS1-treated HSFs. (B) GSEA of DEGs in TBMS1-treated HSFs. Pathways related to PI3K/AKT pathway and ferroptosis are presented. (C) The heatmap shows typical TBMS1-regulated ferroptosis genes in HSFs. (D) The expression of the mRNAs of DEGs associated with ferroptosis in HSFs treated with vehicle or TBMS1 was estimated by qRT-PCR. (E) HSFs were treated with TBMS1 or TBMS1 combined with 1 µM ferrostatin-1, 10 µM Z-VAD-FMK, or 1 μM necrosulfonamide for 48 h before the measurement of cell viability (n = 3 separate assays). (F) ROS and MDA levels, intracellular Fe 2+ contents, and the GSH/GSSG ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (G) ROS and MDA levels, intracellular Fe 2+ contents, and GSH/GSSG ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). (H) Western blotting illustrated TFR1 and DMT1 levels within HSFs after vehicle or TBMS1 treatment. (I) the Fe 2+ /Fe 3+ ratio in vehicle-treated or TBMS1-treated HSFs (n = 3 separate assays). (J) the Fe 2+ /Fe 3+ ratio of HSFs after treatment with TBMS1 or TBMS1 combined with ferrostatin-1 (1 µM) (n = 3 separate assays). The data suggest mean ± SD. Experiments (E–J) were examined via one-way ANOVA based on Tukey’s multiple comparison test, whereas assay (D) was performed via an unpaired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, and ***P < 0.001.

    Article Snippet: After inoculation (1.2 × 10 6 /well) in six-well plates, the cells were subjected to relevant treatments for 48 h. Intracellular Fe 2+ contents were analyzed with the ferrous iron colorimetric assay kit (E-BC-K881-M, Elabscience, Wuhan, China).

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Comparison, Two Tailed Test